Identifying the effects of ABCG2 and ABCB1 polymorphisms on sunitinib-induced toxicity and efficacy in patients with RCC could help to optimize the therapeutic management strategy and maximize the clinical benefits of sunitinib. This evidence concerns the gene ABCB1 and renal cell carcinoma.